Last updated on May 2008

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non Small Cell Lung Cancer
  • Age: Between 20 - 85 Years
  • Gender: Male or Female
  • Other:
    Disease characteristics
    Advanced or recurrent non small cell lung cancer
    Second line or later therapeutic status Patient characteristics
    ECOG performance status 0-2
    Life expectancy > 3 months
    HLA-A*0201
    Laboratory values as follows
    2000/mm3 Platelet count>100000/mm3
    Bilirubin < 3.0mg/dl
    Asparate transaminase < 150IU/L
    Alanine transaminase < 150IU/L
    Creatinine < 3.0mg/dl
    Able and willing to give valid written informed consent

You may not be eligible for this study if the following are true:

  • Pregnancy(woman of childbearing potential:Refusal or inability to use effective means
    of contraception)
    Breastfeeding
    Active or uncontrolled infection
    Unhealed external wound
    Concurrent treatment with steroids or immunosuppressing agent
    Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks
    Uncontrolled brain and/or intraspinal metastasis
    Decision of unsuitableness by principal investigator or physician-in-charge

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.